- Wykrzykowska Joanna J., Kraak Robin P., Hofma Sjoerd H., van der Schaaf Rene J., Arkenbout E. Karin, Ijsselmuiden Alexander J., Elias Joëlle, van Dongen Ivo M., Tijssen Ruben Y. G., Koch Karel T., Baan Jan, Vis M. Marije, de Winter Robbert J., Piek Jan J., Tijssen Jan G. P., Henriques Jose P. S. Bioresorbable Scaffolds versus Metallic Stents in Routine PCI New England journal of medicine 2017;376 (24):2319-2328 [PubMed]
- Ouweneel Dagmar M., Eriksen Erlend, Sjauw Krischan D., van Dongen Ivo M., Hirsch Alexander, Packer Erik J. S., Vis M. Marije, Wykrzykowska Joanna J., Koch Karel T., Baan Jan, de Winter Robbert J., Piek Jan J., Lagrand Wim K., de Mol Bas A. J. M., Tijssen Jan G. P., Henriques José P. S. Percutaneous Mechanical Circulatory Support Versus Intra-Aortic Balloon Pump in Cardiogenic Shock After Acute Myocardial Infarction Journal of the American College of Cardiology 2017;69 (3):278-287 [PubMed]
- Ouweneel Dagmar M., Schotborgh Jasper V., Limpens Jacqueline, Sjauw Krischan D., Engström A. E., Lagrand Wim K., Cherpanath Thomas G. V., Driessen Antoine H. G., de Mol Bas A. J. M., Henriques José P. S. Extracorporeal life support during cardiac arrest and cardiogenic shock: a systematic review and meta-analysis Intensive care medicine 2016;42 (12):1922-1934 [PubMed]
- Henriques José P. S., Hoebers Loes P., Råmunddal Truls, Laanmets Peep, Eriksen Erlend, Bax Matthijs, Ioanes Dan, Suttorp Maarten J., Strauss Bradley H., Barbato Emanuele, Nijveldt Robin, van Rossum Albert C., Marques Koen M., Elias Joëlle, van Dongen Ivo M., Claessen Bimmer E. P. M., Tijssen Jan G., van der Schaaf René J., Zijlstra Felix, de Boer Menko-Jan, Michels Rolf, Meuwissen Martijn, Agostoni Pierfrancesco, van Houwelingen K. Gert, Verberne Hein J., Hirsch Alexander, Piek Jan J., de Winter Robbert J., Koch Karel T., Vis Marije M., Baan Jan, Wykrzykowska Joanna, Slagboom Ton, Amoroso Giovanni, Tuseth Vegard, Schotborgh Carl E., Bertrand Olivier, van der Ent Martin, Koolen Jacques Percutaneous Intervention for Concurrent Chronic Total Occlusions in Patients With STEMI: The EXPLORE Trial Journal of the American College of Cardiology 2016;68 (15):1622-1632 [PubMed]
- Kikkert Wouter J., van Geloven Nan, van der Laan Mariet H., Vis Marije M., Baan Jan, Koch Karel T., Peters Ron J., de Winter Robbert J., Piek Jan J., Tijssen Jan G. P., Henriques José P. S. The prognostic value of bleeding academic research consortium (BARC)-defined bleeding complications in ST-segment elevation myocardial infarction: a comparison with the TIMI (Thrombolysis In Myocardial Infarction), GUSTO (Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries), and ISTH (International Society on Thrombosis and Haemostasis) bleeding classifications Journal of the American College of Cardiology 2014;63 (18):1866-1875 [PubMed]
2016 Professor of Interventional Cardiology with focus on Cardiogenic Shock
2013 AMC Principal Investigator
2011 Master of Business and Administration. MBA degree. University of Massachusetts, USA.
2003 Doctor’s degree (Ph.D)
Title of dissertation: “Primary PCI for acute myocardial infarction. Clinical and angiographic features.” University of Groningen.
Promotor: prof. dr. F. Zijlstra
1984 - 1992 Medical School, Medical Degree, Faculty of Medicine, University of Amsterdam
2008-present Head of Catheterization Laboratory, Academic Medical Center
2003-2005 Fellowship interventional cardiology, Academic Medical Center
2003 Staff Cardiologist, Academic Medical Center
1997-2003 Trainee residency Cardiology, Sophia Hospital and Ziekenhuis de Weezenlanden, Zwolle. (Dr. J.C.A. Hoorntje)
1996 Residency Cardiology, Sophia Hospital, Zwolle
1994-1995 Residency Cardiothoracic Surgery, St Antonius ziekenhuis, Nieuwegein
1993-1994 Residency Cardiothoracic Surgery, OLVG Hospital, Amsterdam,
1992-1993 House Officer at different departments in England
2016 BROK (Good Clinical Practice) re-registration
2016 Teach the teacher (Feedback)
2014 Academic Medical Center Leadership program
2012 BROK (Basiscursus Regelgeving and Organisatie Klinisch Onderzoekers)
2010 Teach the teacher
2007 TOEFL. Test of English as a foreign language. (Score 115/120)
2007 Master of Medical Management. ACPE – section I
2002 Cursus Klinische Epidemiologie Schiermonnikoog (LUMC)
Acquired Funding/ Research Grants (M = main applicant, C = Co-applicant)
2014: M: Abbott Vascular (AIDA) (k€1400)
2014: C: NWO (QvL) (k€400)
2014: M: InspireMD (Master II) (k€120)
2013: M: Abiomed Inc. (PhDgrant) (k€120)
2012: M: Abiomed Inc. (Japan FUP) (k€20)
2011: M: Abiomed Inc. (FIM RP) (k€26)
2010: M: Bbraun Medical (DARE) (k€890)
2010: M: Abbott Vascular (IECR) (k€23)
2009: M: Abiomed Inc. (MACH 3) (k€150)
2008: M: NUTS OHRA (less bleeds) (k€81)
2007: M: Abiomed Inc. (MACH) (k€172)
2007: M: Abbott Vascular (Explore) (k€1400)
2007: M: Abiomed Inc. (Impress) (k€1000)
2006: M: Novo Nordisk (Glirami) (k€132)
Supervisor PhD students University of Amsterdam
R.J. van der Schaaf “Clinical Outcomes in high-risk STEMI patients with Mulitvessel Disease”
2010, May 20
K.D. Sjauw “Percutaneous Mechanical Cardiac Assist Devices in Acute Myocardial Infarction and High-Risk PCI” 2010 November 19,
B.E.P.M. Claessen “Prognostic Factors in Primary and Elective Percutaneous Coronary
Intervention” 2011, October 5
A.E. Engstrom “Percutaneous Mechanical Support Percutaneous Mechanical circulatory
Support for Treatment and Prevention of Hemodynamic Instability” 2012, June 29
M.M. Vis “Cardiogenic Shock in Acute Myocardial Infarction. Clinical outcome and
predictors” 2012, November 9
W.J. Kikkert “Ischemic events and bleeding complications after primary percutaneous
coronary intervention” 2015, January 30
L.P.C. Hoebers (2016)
D.M. Ouweneel (2016)
I.M. van Dongen (2017)
K.Y. Lam (2017)
J.E Elias (2018)
International opponent/reading committee PhD defence
Vegard Tuseth “Percutaneous left ventricular assist device in cardiac arrest”, Faculty of Medicine, University of Bergen, Norway, 2009 December 16
Grete Slettom “A systematic approach to the use of Insulin to prevent repefusion injury in
porcine ST elevation myocardial infarction”, Faculty of Medicine, University of Bergen, Norway, 2014 October 27
Supervision of BSc/MSc students, Faculty of Medicine University of Amsterdam
Karlijn Boots Faculty of Medicine AMC, Planned graduation in 2016
Justin de Brabander Faculty of Medicine AMC, graduated in 2015
Jasper Schotborgh Faculty of Medicine AMC, graduated in 2015
Anna van Haersma de With Faculty of Medicine AMC, graduated in 2011
Fleur Tjong Faculty of Medicine AMC, graduated in 2008
Willy Boom, Faculty of Medicine AMC, graduated in 2007
Carolien Geesink, Faculty of Medicine AMC, graduated in 2007
Alexander Maccloud, Faculty of Medicine AMC, graduated in 2006
Nienke Stegenga, Faculty of Medicine AMC, graduated in 2006
Marjan Mangal, Faculty of Medicine AMC, graduated in 2006
Supervision of BSc/MSc students other Universities
Robin Wesslink Faculty of Technical Medicine, University of Twente, 2016
Wouter Kikkert Faculty of Medicine, University of Groningen, graduated in 2010
Krischan D Sjauw Faculty of Medicine, University of Groningen, graduated in 2005
Second prize of The Einthoven dissertation award for best dissertation of the year 2003.
Isala Werkpaard Award for best publication of the year 1999
International Research Network Activities
2016- present Collaboration on PhD project (M Frydland) on biomarkers in AMC cardiogenic shock database. Prof. dr C. Hassager, University of Copenhagen, Denmark.
2011 - 2012 Collaboration on PhD project (LP Hoebers) on the SCAAR database with Prof. dr E. Olmerovic and dr. T Remundal, University of Gothenburg, Sweden.
2010 - 2011 Collaboration on PhD project (BE Claessen) on a range of projects with Prof. dr G. Dangas and Prof.dr. G.W. Stone, Columbia University, New York, USA
2001- 2003 Collaboration on PhD project University of Gent, Belgium (prof.dr. P. Gheeraert)
1992 Junior researcher, Experimental Physiology, University of Lisbon, Portugal
Organizational (AMC) Network activities
Integrated member of the management team of the AMC Heartcenter Division.
Initiator and coordinator of potential collaboration (AMC/OLVG) setting up PCI facility on Aruba
Membership of editorial boards
2010 - present Journal Medical Sciences
2011 - present Journal of Geriatric Cardiology
Membership of professional societies
Netherlands Society of Cardiology
Working Group on Interventional Cardiology of the European Society of Cardiology
Member of the European Society of Cardiology
Membership of Scientific committees
Bleemacs registry (2015-present)
TransCatheter Therapeutics (TCT) meeting (2014- present)
Dutch revascularization and Electrophysiology Summit (2012-present)
Member of the scientific activities committee, Acute Cardiac Care Association (2012-2015)
Reviewer for The Danish Council for Strategic Research. (2012)
Amsterdam (AMC;VUMC;OLVG) Regional PCI Complication meetings (3x/year; 2013-present)
4th Indo European Course on Revascularization, August 24-26, 2010
1st Annual Chronic Total Occlusion Symposium, November 13 2009
Percutaneous valve Procedures, October 9, 2009
AMC CTO Summit, November 21, 2008
University of Amsterdam for the Medical School/Curriculum. Cardiogenic shock.
Formal supervisor of subspecialty fellowship interventional cardiology.
Over 200 presentations worldwide.
Over 50 invited lectures at scientific meetings such as European Society of Cardiology (ESC), EuroPCR, Transcatheter Therapeutics (TCT), American college of Cardiology (ACC), American Heart Association (AHA), Society for Cardiovascular Angiography and Interventions (SCAI) and various (inter)-national scientific society meetings
Selection of subjects
Acute Myocardial infarction
Percutaneous coronary intervention
Circulatory support devices
Multivessel coronary artery disease
Chronic total occlusion
International peer reviewed scientific publications: See Appendix
Hirsch Index: 35
Howard Cohen and Jose PS Henriques (editors). Percutaneous Ventricular Support, An issue of
Interventional Cardiology Clinics. Elsevier, Philadelphia, 2013.
Rationale and Technique for Percutaneous Coronary Intervention of Chronic Total Occlusions. In: Lanzer, P (Ed). Panvascular Medicine (2281-2297) Springer, London, 2014
BE Claessen and JPS Henriques. Vasoactive and antiarrhythmic drugs during percutaneous coronary
intervention. In: Dangas, GD (Ed). Interventional Pharmacology, An issue of Interventional Cardiology Clinics, 1st Edition. (665-671) Elsevier, Philadelphia, USA, 2013
D Burkhoff, M Moscucci, JPS Henriques..Percutaneous Circulatory Support: Intra-Aortic Balloon
Counterpulsation, Impella, TandemHeart and Extracorporeal Bypass. In: Moscucci, M (Ed). Baim & Grossman's Cardiac Catheterization, Angiography, and Intervention, 8th ed. (601-627). Lippincott Williams & Wilkins, Philadelphia, USA 2012
JPS Henriques. Left ventricular support for STEMI interventions. In: Mehta, S (Ed). Textbook of STEMI
interventions. HMP Communications, USA, 2012.
AE Engström, SS Basra, B. Kar, JPS Henriques Percutaneous left ventricular assist devices. Past, Present
and Future. In: Sabaté, M (Ed). Percutaneous Cardiac Interventions beyond stenting. Tips and tricks for new technology. PCR publishing / EUROPA EDITION, 2010
JPS Henriques. Haemodynamic support in high-risk patients. In: De Luca, G. and Lansky, A. (Eds).
Mechancial Reperfusion For STEMI: From Randomized Trial to Clinical Practice.(162-170). CRC Press, USA, 2010
JPS Henriques. Left ventricular support for STEMI interventions. In: Mehta S. (Ed). Textbook of STEMI
interventions. 2008. (317-327). HMP Communications, USA, 2008
Reviewer for journals (selection)
New England Journal of Medicine
Circulation Cardiovascular interventions
Journal of American College of Cardiology
Journal of American College of Cardiology Cardiovascular interventions
European Heart Journal
European Journal of Heart Failure
American Journal of Cardiology
International Journal of Cardiology
Reviewer for funding agencies/research councils
Global CVAD registry
Abiomed Protect II trial
Abiomed Protect I trial
Member of the Global Impella Steering Committee
Abiomed Inc (2005- present)
The Medicine company (2012)
Principal investigator of clinical trials
AIDA trial. Amsterdam Investigator-initiateD Absorb Strategy All-comers Trial (AIDA Trial): A Clinical
Evaluation Comparing the Efficacy and Performance of ABSORB™ Everolimus Eluting Bioresorbable Vascular Scaffold Strategy Versus the XIENCE Family (XIENCE PRIME™ or XIENCE Xpedition™) Everolimus Eluting Coronary Stent Strategy in the Treatment of Coronary Lesions in Consecutive All-comers. (Co-Principal investigator)
Master II trial “MGuard™ Prime Stent System Clinical Trial in Patients with Acute ST Elevation Myocardial
Infarction” (Co-Principal investigator)
Explore trial. An European Multi-center, randomized trial to study the impact of percutaneous coronary
intervention on left ventricular function in patients with a non-infarct related chronic total occlusion after ST-elevation myocardial infarction: PCI vs. conservative approach in CTO patients after STEMI. (Chairman, Principal Investigator).
Impress in Severe Shock trial. A multicenter, randomized trial of the Impella cVAD versus Intra Aortic
Balloon Counter Pulsation (IABP) therapy for acute ST-elevation myocardial infarction patients treated with primary PCI in severe and deep cardiogenic shock. (Chairman, Principal Investigator).
DARE trial. DARE-Trial Drug eluting bAlloon for in-stent Restenosis. Multi-center, randomized trial to
study the effect of the SeQuent Please drug-eluting balloon versus the Xience Prime drug-eluting stent for the treatment of in-stent restenosis. (Co-Principal investigator)
Use of the Impella RP 4.0 in patients with right ventricular failure. FIRST IN MAN clinical trial.
(Chairman, Principal Investigator).
Impress in STEMI Trial. An European Multi-center, randomized trial of the Impella* recover LP 2,5 (left
ventricular assist) device versus Intra Aortic Balloon Counter Pulsation (IABP) therapy for large anterior acute ST-elevation myocardial infarction patients treated with primary PCI. (Chairman, Principal Investigator).
Paradigm trial. A single-center, randomized trial of the strict glycaemic control in ST-elevation
myocardial infarction patients with the Paradigm® Real-Time system versus routine therapy. (Co-Principal investigator)
Local Principal Investigator of clinical trials
Prison 4 trial. Hybrid Sirolimus-eluting stent with bioresorbable polymer versus Everolimus –eluting stent
with durable polymer for total coronary occlusions in native coronary arteries. Primary Stenting of Occluded Native Coronary Arteries IV. (PRISON IV)
HEBE 3 study. A Single Dose of Erythropoietin in ST-elevation Myocardial Infarction.
Prison 3 trial. A randomized comparison of sirolimus-eluting stent implantation with zotarolimus-eluting
stent implantation for the treatment of total coronary occlusions: rationale and design of the PRImary Stenting of Occluded Native coronary arteries III (PRISON III) study
DAPA (Defibrillator After Primary Angioplasty) – Randomized Trial. Implantable Defibrillator early after
Primary PCI for ST-Elevation Myocardial Infarction.
The Glucose-Insulin-Potassium Study (GIPS)-II Glucose-insulin-potassium infusion in patients with acute
myocardial infarction without signs of heart failure.
European Principal Investigator in Global Clinical trial
TOSCA 5 (CTO-201) A 2-stage study to evaluate single doses of MZ-004 at different dose levels in patients with chronic
total occlusions. (Single non US center)
ABIOMED PROTECT II (Food Drug Administration Pivotal Trial). Randomized trial to study safety and
effectiveness of the Impella 2.5 as compared to optimal medical management with an Intra-Aortic Balloon Pump (IABP) during "high-risk" angioplasty procedures. (Single non US center)
ABIOMED PROTECT I (Food Drug Administration Approval Trial). A Prospective Feasibility Trial
Investigating the use of the IMPELLA® RECOVER® LP 2.5 System in Patients Undergoing
High Risk PCI. IDE Number: G050017. (Single non US center)
Prof. J.P. Simao Henriques MD PhD (Low circulatory output in acute coronary syndromes)
Acute myocardial infarction
In the Netherlands, 28500 patients suffer from an acute myocardial infarction every year and around 2400 patients present with cardiogenic shock.
Cardiogenic shock is a state of insufficient circulation to the organs due to poor pump function of the heart. This condition requires intensive care management, including mechanical ventilation, renal function replacement (dialysis), and various other supportive therapies.
Despite all efforts, these patients have a poor prognosis with a short term mortality of around 50%. Pharmacological support and the use of intra-aortic counterpulsation (IABP) improve hemodynamic parameters, but have failed to demonstrate better outcome in patients with cardiogenic shock.
A temporary heartpump during the acute event may support the heart and circulation until the heart is recovered and able to resume its function. Especially nowadays where all patients with an acute myocardial infarction undergo immediate revascularization, recovery is a real option. Temporary heartpumps can support the circulation during a limited time period, up one or two weeks
The clinical course of these patients can be summarized into 3 categories:
1) functional recovery, after which the patient can leave the hospital
2) insufficient cardiac recovery with need for a permanent cardiac function replacement by a permanent surgical left ventricular assist device (LVAD or in dutch ‘steunhart’) or heart transplantation
3) death as a result of heart failure, multi-organ failure or other complications.
It is clear that the best option for the patient is functional recovery. Biochemical and hemodynamic parameters that predict clinical outcome are needed to predict and further define patients that respond to temporary mechanical assistance.
An open Coronary Artery is always better than an occluded one
An acute occlusion of a coronary artery is the main reason for an acute myocardial infarction. In the Netherlands, 28500 patients suffer from an acute myocardial infarction every year. Half of these patients have additional coronary artery disease, defined as multivessel disease. A total of 10% of all patients with an acute myocardial infarction have an additional chronic total coronary occlusion. These patients have reduced pump function and additional revascularization may improve the pumping and overall function of the heart. It is important to further define those patients who might benefit from such therapy in a variety of clinical entities
B.E.P.M. Claessen MD PhD
W.J. Kikkert PhD
M.M. Vis PhD
- Abbott B.V.
- Abbott Vascular International
- AstraZeneca BV
- Crediteurenadm. VUmc, p/a Profource Service Center
- Getinge Netherlands B.V.
- Medinol Ltd.
- Medtronic Bakken Research Center BV
- NIEUWE DEB IND